Your browser doesn't support javascript.
loading
Role of primary care in opioid prescribing for older head and neck cancer survivors.
Salz, Talya; Meza, Akriti Mishra; Bradshaw, Patrick T; Jinna, Sankeerth; Moryl, Natalie; Kriplani, Anuja; R Tringale, Kathryn; Flory, James; Korenstein, Deborah; Lipitz-Snyderman, Allison.
Afiliación
  • Salz T; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Meza AM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Bradshaw PT; University of California Berkeley, Berkeley, California, USA.
  • Jinna S; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Moryl N; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kriplani A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • R Tringale K; University of California San Diego School of Medicine, San Diego, California, USA.
  • Flory J; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Korenstein D; Mount Sinai Hospital, New York, New York, USA.
  • Lipitz-Snyderman A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cancer ; 2024 Jul 27.
Article en En | MEDLINE | ID: mdl-39072710
ABSTRACT

BACKGROUND:

Older head and neck cancer (HNC) survivors have concerning rates of potentially unsafe opioid prescribing. Identifying the specialties of opioid prescribers for HNC survivors is critical for targeting the settings for opioid safety interventions. This study hypothesized that oncology and surgery providers are primarily responsible for opioid prescriptions in the year after treatment but that primary care providers (PCPs) are increasingly involved in prescribing over time.

METHODS:

Using linked Surveillance, Epidemiology, and End Results-Medicare data, a retrospective analysis was conducted of adults aged >65 years diagnosed between 2014 and 2017 with stage I-III HNC and who had ≥6 months of treatment-free follow-up through 2019. Starting at treatment completion, opioid fills were assigned to a prescriber specialty oncology, surgery, primary care, pain management, or other. Prescriber patterns were summarized for each year of follow-up. Multinomial logistic regression models captured the likelihood of opioids being prescribed by each specialty.

RESULTS:

Among 5135 HNC survivors, 2547 (50%) had ≥1 opioid fill (median, 2.1-year follow-up). PCPs prescribed 47% of all fills (42%-55% each year). PCPs prescribed opioids to 45% of survivors with ≥1 opioid fill, which was a greater share than other specialties. PCPs prescribed longer supplies of opioids (median, 20 days/fill; median, 30 days/year) than oncologists or surgeons. The likelihood of an opioid being prescribed by an oncology provider was four times lower than that of it being prescribed by a PCP.

CONCLUSIONS:

PCP involvement in opioid prescribing remains high throughout HNC survivorship. Interventions to improve the safety of opioid prescribing should target primary care, as is typical for opioid reduction efforts in the noncancer population.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos